Albert Bourla has served as chairman and chief executive officer of Pfizer since January 2019. He joined the company in 1993 and held leadership roles across global commercial operations, vaccines, oncology and research and development. As Group President of Pfizer Innovative Health he oversaw vaccines, oncology, rare disease, inflammation and immunology, and consumer health, and led the company’s strategic pivot toward high‑growth therapeutic areas. Under his leadership Pfizer has emphasized innovation-driven medicines, expanded global partnerships and improved operational efficiency, reinforcing its position among leading biopharmaceutical companies.
A defining achievement of Bourla’s tenure was the rapid development, regulatory approval and global distribution of the COVID-19 mRNA vaccine, developed with BioNTech and delivered in the billions of doses worldwide. He has also expanded Pfizer’s oncology portfolio through strategic acquisitions and collaborations, advanced digital approaches in R&D and manufacturing, and implemented corporate restructuring to prioritize high-impact research.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025 some lead the world’s largest cancer institutions; others guide professional societies or emerging innovators. They are united by responsibility for millions of patients, the integrity of science and the future direction of cancer care globally.
This list is intended as recognition of stewardship, accountability and impact rather than a celebration of power. The many deserving leaders not mentioned will continue to be acknowledged, honored and elevated in our daily publications from around the world.
Leave a Reply